-+ 0.00%
-+ 0.00%
-+ 0.00%

CSPC Group announced that the recombinant all-human anti-Act RIIA/IIB monoclonal antibody developed by the Group has been approved by the US Food and Drug Administration and can conduct clinical trials in the US. The product was also approved by the State Drug Administration of the People's Republic of China to conduct clinical trials in China in November 2025.

Zhitongcaijing·12/10/2025 10:25:07
Listen to the news
CSPC Group announced that the recombinant all-human anti-Act RIIA/IIB monoclonal antibody developed by the Group has been approved by the US Food and Drug Administration and can conduct clinical trials in the US. The product was also approved by the State Drug Administration of the People's Republic of China to conduct clinical trials in China in November 2025.